XPH logo

SPDR S&P Pharmaceuticals ETF (XPH)

$65.36

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on XPH

AUM

$516361647

P/E ratio

15

Dividend yield

0.7841%

Expense ratio

0.35%

Beta

0.625238

Price on XPH

Previous close

$66.83

Today's open

$66.85

Day's range

$65.21 - $67.14

52 week range

$50.95 - $74.35

Profile about XPH

show more

Headquarters

US

Exchange

NYSE Arca

Issue type

Exchange-Traded Fund

XPH industries and sectors

Industries

Health

News on XPH

Which Healthcare ETF Is Best for the Long Term: State Street's XPH or Invesco's PBE?

State Street SPDR S&P Pharmaceuticals ETF provides a more diversified and lower-cost entry to the healthcare sector than its Invesco counterpart. Invesco Biotechnology & Genome ETF focuses on a narrower set of biotechnology stocks and offers a significantly higher dividend yield.

news source

The Motley Fool • Nov 15, 2026

news preview

Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street's XPH or First Trust's FBT?

State Street SPDR S&P Pharmaceuticals ETF offers a lower expense ratio of 0.35% compared to 0.55% for the First Trust fund. First Trust NYSE Arca Biotechnology Index Fund has delivered higher total returns over the past one-year and five-year periods.

news source

The Motley Fool • Nov 11, 2026

news preview

How to Invest in the Rise of China's Biotech: Buy U.S. Drug Stocks

Many of the hot new drug candidates in the U.S. were developed Chinese companies.

news source

Barrons • Nov 3, 2026

news preview

Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF

VanEck Pharmaceutical ETF provides a higher dividend yield and lower price volatility compared to the State Street fund. State Street SPDR Pharmaceuticals ETF offers a more diversified portfolio with more than twice as many individual holdings.

news source

The Motley Fool • Oct 30, 2026

news preview

Which Healthcare ETF Is the Better Buy: State Street's Pharma XPH or Simplify's Mission-Driven PINK?

State Street SPDR S&P Pharmaceuticals ETF offers a lower expense ratio but has a lower dividend yield than Simplify Health Care ETF. Simplify Health Care ETF has shown significantly lower maximum drawdowns than the SPDR fund over the last five years.

news source

The Motley Fool • Oct 26, 2026

news preview

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

The State Street SPDR S&P Pharmaceuticals ETF (XPH) made its debut on 06/19/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

news source

Zacks Investment Research • Oct 21, 2026

news preview

XPH: Healthcare Sector Dashboard For October

Pharmaceuticals/biotechnology are currently overvalued by 14% versus 11-year averages, while healthcare equipment appears undervalued despite recent value score deterioration. State Street SPDR S&P Pharmaceuticals ETF offers diversified pharma exposure with low company-specific risk due to its modified equal-weight methodology. XPH is best suited for tactical allocation or swing trading, not as a compelling long-term holding, given its historical risk-return profile and sector dynamics.

news source

Seeking Alpha • Oct 16, 2026

news preview

Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma

The VanEck Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF both carry an identical expense ratio of 0.35%. The State Street SPDR S&P Pharmaceuticals ETF is more diversified with 62 holdings, while the VanEck Biotech ETF focuses on 25 holdings.

news source

The Motley Fool • Oct 10, 2026

news preview

Better Pharma ETF: iShares IHE vs. State Street XPH

The iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio. The iShares U.S. Pharmaceuticals ETF provides a higher dividend yield of 1.4% compared to 0.4% for the State Street SPDR S&P Pharmaceuticals ETF.

news source

The Motley Fool • Oct 10, 2026

news preview

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on June 19, 2006.

news source

Zacks Investment Research • Oct 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in SPDR S&P Pharmaceuticals ETF

Open an M1 investment account to buy and sell SPDR S&P Pharmaceuticals ETF commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in XPH on M1